Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,556 Mln
Revenue (TTM)
$868 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
9.9
P/B Ratio
1.8
Industry P/E
--
EV/EBITDA
3.9
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$14.7
EPS
$2.7
Face value
--
Shares outstanding
57,840,614
CFO
$345.19 Mln
EBITDA
$269.14 Mln
Net Profit
$95.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Harmony Biosciences Holdings (HRMY)
| -25.9 | -2.8 | -25.9 | -14.4 | -5.3 | -2.9 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Harmony Biosciences Holdings (HRMY)
| 8.7 | 6.5 | -41.4 | 29.2 | 18.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Harmony Biosciences Holdings (HRMY)
|
27.7 | 1,555.9 | 868.5 | 158.7 | 26.0 | 20.8 | 9.9 | 1.8 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 24.7 | 2,922.9 | 589.0 | 214.3 | 46.8 | 25.5 | 14.2 | 2.9 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule... with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 Read more
Founder & Non-Executive Chairman
Mr. Jeffrey S. Aronin
Founder & Non-Executive Chairman
Mr. Jeffrey S. Aronin
Headquarters
Plymouth Meeting, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Harmony Biosciences Holdings (HRMY) is $27.74 (NASDAQ) as of 02-Apr-2026 17:55 EDT. Harmony Biosciences Holdings (HRMY) has given a return of -5.29% in the last 3 years.
The P/E ratio of Harmony Biosciences Holdings (HRMY) is 9.93 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.91
|
2.54
|
|
2024
|
13.72
|
3.03
|
|
2023
|
15.04
|
4.15
|
|
2022
|
18.52
|
8.34
|
|
2021
|
72.72
|
13.49
|
The 52-week high and low of Harmony Biosciences Holdings (HRMY) are Rs 40.87 and Rs 25.52 as of 05-Apr-2026.
Harmony Biosciences Holdings (HRMY) has a market capitalisation of $ 1,556 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Harmony Biosciences Holdings (HRMY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.22
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.